AZN.UK

11,924

+0.59%↑

GSK

1,482

+2.38%↑

AZN.UK

11,924

+0.59%↑

GSK

1,482

+2.38%↑

AZN.UK

11,924

+0.59%↑

GSK

1,482

+2.38%↑

AZN.UK

11,924

+0.59%↑

GSK

1,482

+2.38%↑

AZN.UK

11,924

+0.59%↑

GSK

1,482

+2.38%↑

Search

Oxford Biomedica PLC

Atvērts

593

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

561

Max

594

Galvenie mērījumi

By Trading Economics

Ienākumi

-11M

Pārdošana

78M

EPS

-0.11

Peļņas marža

-13.726

Darbinieki

850

EBITDA

5M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+4.62% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 23. sept.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

690M

Iepriekšējā atvēršanas cena

593

Iepriekšējā slēgšanas cena

593

Oxford Biomedica PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 8. sept. 23:59 UTC

Iegādes, apvienošanās, pārņemšana

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

2025. g. 8. sept. 22:02 UTC

Galvenie tirgus virzītāji

Microsoft Signs $17.4 Billion AI Deal With Nebius

2025. g. 8. sept. 17:01 UTC

Galvenie tirgus virzītāji

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

2025. g. 8. sept. 17:01 UTC

Galvenie tirgus virzītāji

Tron Shares Rise After New Investment From Bravemorning

2025. g. 8. sept. 16:14 UTC

Galvenie tirgus virzītāji

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

2025. g. 8. sept. 16:13 UTC

Galvenie tirgus virzītāji

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

2025. g. 8. sept. 23:12 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 8. sept. 23:12 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 8. sept. 23:12 UTC

Tirgus saruna

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

2025. g. 8. sept. 22:56 UTC

Tirgus saruna

Worst May Be Over for New Zealand Retailers -- Market Talk

2025. g. 8. sept. 22:23 UTC

Tirgus saruna

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

2025. g. 8. sept. 21:51 UTC

Tirgus saruna

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

2025. g. 8. sept. 21:47 UTC

Galvenie tirgus virzītāji

Microsoft Signs $17.4B AI Deal With Nebius

2025. g. 8. sept. 21:33 UTC

Iegādes, apvienošanās, pārņemšana

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

2025. g. 8. sept. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

2025. g. 8. sept. 21:19 UTC

Iegādes, apvienošanās, pārņemšana

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

2025. g. 8. sept. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

2025. g. 8. sept. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 8. sept. 19:33 UTC

Tirgus saruna

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

2025. g. 8. sept. 19:22 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Higher -- Market Talk

2025. g. 8. sept. 19:02 UTC

Tirgus saruna

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

2025. g. 8. sept. 18:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 8. sept. 18:24 UTC

Tirgus saruna

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

2025. g. 8. sept. 17:29 UTC

Tirgus saruna

Mexican Inflation Seen Little Changed in August -- Market Talk

2025. g. 8. sept. 16:59 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

2025. g. 8. sept. 16:36 UTC

Tirgus saruna

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

2025. g. 8. sept. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 8. sept. 16:16 UTC

Peļņas

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

2025. g. 8. sept. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 8. sept. 16:04 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Oxford Biomedica PLC Prognoze

Cenas mērķis

By TipRanks

4.62% augšup

Prognoze 12 mēnešiem

Vidējais 618.322 GBX  4.62%

Augstākais 932.152 GBX

Zemākais 400.926 GBX

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Oxford Biomedica PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

3

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Oxford Biomedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
help-icon Live chat